Knott David M Jr Viking Therapeutics, Inc. Transaction History

Knott David M Jr

$283 Million
Q1 2024

A detailed history of Knott David M Jr transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Knott David M Jr holds 101,436 shares of VKTX stock, worth $5.38 Million. This represents 2.94% of its overall portfolio holdings.

Number of Shares

101,436

Previous 270,822 62.55%

Holding current value

$5.38 Million

Previous $5.04 Million 65.04%

% of portfolio

2.94%

Previous 1.93%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$17.4 - $94.5 $2.95 Million - $16 Million	-169,386 Reduced 62.55%	101,436 $8.32 Million
Q4 2023 Feb 13, 2024	BUY	$9.24 - $19.64 $787,867 - $1.67 Million	85,267 Added 45.95%	270,822 $5.04 Million
Q3 2023 Nov 13, 2023	BUY	$10.92 - $16.0 $1.2 Million - $1.76 Million	110,006 Added 145.61%	185,555 $2.05 Million
Q2 2023 Aug 11, 2023	SELL	$14.84 - $24.79 $1.85 Million - $3.09 Million	-124,615 Reduced 62.26%	75,549 $1.23 Million
Q1 2023 May 11, 2023	SELL	$8.08 - $17.33 $1.47 Million - $3.14 Million	-181,457 Reduced 47.55%	200,164 $3.33 Million

Q4 2022 Feb 13, 2023	BUY	$2.72 - $9.4 $217,104 - $750,289	79,818 Added 26.45%	381,621 $3.59 Million
Q3 2022 Nov 10, 2022	BUY	$2.55 - $3.89 $89,250 - $136,150	35,000 Added 13.12%	301,803 $821,000
Q2 2022 Aug 11, 2022	BUY	$2.11 - $3.15 $81,659 - $121,908	38,701 Added 16.97%	266,803 $771,000
Q1 2022 May 16, 2022	BUY	$3.0 - $4.88 $60,000 - $97,600	20,000 Added 9.61%	228,102 $684,000
Q4 2021 Feb 11, 2022	BUY	$4.6 - $6.72 $957,269 - $1.4 Million	208,102 New	208,102 $957,000

Others Institutions Holding VKTX

# of Institutions

426

Shares Held

63.1M

Call Options Held

7.39M

Put Options Held

5.13M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.07B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Knott David M Jr, based on Form 13F filings with the SEC.

News

Stay updated on Knott David M Jr with notifications on news.

Account